Pfizer expects 2021, 2022 COVID-19 vaccine sales to total at least $65 bln
Pfizer Inc on Tuesday said it expected 2021 sales of the COVID-19 vaccine it developed with German partner BioNTech SE to reach $36 billion and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.